

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



PCT

(43) International Publication Date
13 July 2006 (13.07.2006)

(10) International Publication Number
WO 2006/073413 A1

(51) International Patent Classification:
A61K 31/40 (2006.01) *A61P 9/12* (2006.01)

(74) Agent: NOONAN, Kevin, E.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(21) International Application Number:
PCT/US2005/005626

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
22 February 2005 (22.02.2005)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
60/546,227 20 February 2004 (20.02.2004) US
60/549,289 2 March 2004 (02.03.2004) US

(71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS [US/US]; 352 Henry Administration Building, 506 South Wright Street, Urbana, IL 61801 (US).

Published:
— with international search report

[Continued on next page]

(54) Title: BLOOD PRESSURE REDUCTION IN SALT-SENSITIVE



Effect of rolipram on blood pressure in salt-sensitive and salt-resistant rats.

(57) Abstract: This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger cAMP and, therefore, down-regulate beta-adrenergic signaling. Specifically provided are methods and pharmaceutical compositions for treating salt-sensitive hypertension by inhibiting certain members of the PDE4 family of cyclic nucleotide phosphodiesterases, particularly members of the PDE4B and PDE4D sub-families and, more particularly, the PDE4B1 and PDE4D5 isotypes thereof.

WO 2006/073413 A1

WO 2006/073413 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.